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Abstract
Background: We have shown that 1,2,3,4,6-penta-O-galloyl-a-D-glucopyranose (a-PGG), an orally effective hypoglycemic
small molecule, binds to insulin receptors and activates insulin-mediated glucose transport. Insulin has been shown to bind
to its receptors on platelets and inhibit platelet activation. In this study we tested our hypothesis that if insulin possesses
anti-platelet properties then insulin mimetic small molecules should mimic antiplatelet actions of insulin.
Principal Findings: Incubation of human platelets with insulin or a-PGG induced phosphorylation of insulin receptors and
IRS-1 and blocked ADP or collagen induced aggregation. Pre-treatment of platelets with a-PGG inhibited thrombin-induced
release of P-selectin, secretion of ATP and aggregation. Addition of ADP or thrombin to platelets significantly decreased the
basal cyclic AMP levels. Pre-incubation of platelets with a-PGG blocked ADP or thrombin induced decrease in platelet cyclic
AMP levels but did not alter the basal or PGE1 induced increase in cAMP levels. Addition of a-PGG to platelets blocked
agonist induced rise in platelet cytosolic calcium and phosphorylation of Akt. Administration of a-PGG (20 mg kg
21) to wild
type mice blocked ex vivo platelet aggregation induced by ADP or collagen.
Conclusions: These data suggest that a-PGG inhibits platelet activation, at least in part, by inducing phosphorylation of
insulin receptors leading to inhibition of agonist induced: (a) decrease in cyclic AMP; (b) rise in cytosolic calcium; and (c)
phosphorylation of Akt. These findings taken together with our earlier reports that a-PGG mimics insulin signaling suggest
that inhibition of platelet activation by a-PGG mimics antiplatelet actions of insulin.
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Introduction
Patients suffering from diabetes are at a greater risk of
thrombotic complications [1,2,3,4,5,6] and exhibit a much higher
incidence of cardiovascular disease as well as an increased rate of
mortality due to ischemic heart disease [7]. Platelets from diabetic
patients have been shown to exhibit increased adhesion, secretion
and aggregation [8,9,10,11,12], processes that promote throm-
botic complication in diabetics. Increased platelet reactivity in
diabetic patients plays a critical role in initiation and progression of
thrombosis leading to cardiovascular disease, diabetic nephropa-
thy, retinopathy as well as peripheral artery disease [13,14].
Reports that abnormal platelet function (secretion, aggregation)
occurs not only in platelet-rich plasma but also in washed platelets
imply that the mechanism(s) of increased platelet reactivity reside
within the platelets [14]. It has been shown that insulin inhibits
platelet activation [15]. Moreover, the ability of insulin to inhibit
platelet function has been shown to be lacking or diminished in
insulin-resistant patients [16,17,18]. The direct anti-platelet action
of insulin is possibly mediated via regulation of adenylyl cyclase
[15]. ADP or thrombin, agonists that induce platelet aggregation,
lower basal cyclic AMP levels via stimulation of Gia2, a G protein
that inhibits adenylyl cyclase [19]. PGI2 inhibits platelet activation
by stimulating adenylyl cyclase and thereby increasing platelet
cyclic AMP levels [20].
Platelets contain insulin receptors [21] and binding of insulin to
its receptors induces phosphorylation of its b subunits [22,23].
This is followed by activation of insulin receptor substrate 1 (IRS-
1) and subsequent inactivation of Gia2. Inhibition of Gia2 prevents
agonist-induced lowering of cyclic AMP and the rise in cytosolic
calcium, two critical signals for secretion and aggregation of
platelets [15]. In other words insulin prevents platelet activation by
blocking the agonist-induced lowering of cyclic AMP and the
increase in calcium level.
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have the potential to act as therapeutic agents for prevention and
management of diabetes [24,25,26]. L-783,281, a non-peptidyl
fungal metabolite binds to insulin receptors and activates glucose
transport [27]. We have shown that a-PGG is an orally effective
hypoglycemic small molecule that binds to insulin receptors and
activates insulin-mediated glucose transport [28,29]. Here we
report that a-PGG inhibits platelet activation by inducing
phosphorylation of insulin receptors leading to inhibition of
agonist mediated lowering of cyclic AMP, mobilization of cytosolic
calcium and phosphorylation of Akt.
Materials and Methods
Materials
a-PGG was custom synthesized at Ohio University [28,29].
Unless otherwise noted, chemicals and reagents were purchased
from Sigma-Aldrich (St. Louis, MO). Collagen was obtained from
Chrono-Log Corporation (Havertown, PA).
Methods
Collection of blood and preparation of washed platelet
suspensions. All experiments using human blood from healthy
volunteers were performed according to the protocol approved by
the Institutional Review Board (Protocol #07X067) at Ohio
University, Athens, Ohio. Each volunteer was required to sign an
informed consent form approved by the Institutional Review
Board at Ohio University. Experiments utilizing mice blood were
conducted according to the protocol approved by the Institutional
Animal Care and Use Committee (Protocol#H08-02) at Ohio
University Athens, Ohio. Procedures for drawing human blood,
isolation of platelet-rich plasma (PRP) and preparation of washed
platelet suspensions are the same as reported earlier [30]. The
platelet count was adjusted to 3610
8 per ml for aggregation
studies.
The ex vivo anti-platelet actions of a-PGG were investigated in
wild type mice. Blood from mice was drawn by cardiac puncture
from anesthetized wild type mice as reported earlier [30,31],
30 min after oral administration of a-PGG or vehicle, into a
syringe containing 100 ml of 3.8% trisodium citrate. The PRP was
obtained by centrifugation at 90 g for 10 minutes.
Release of P-selectin from a-granules, secretion of ATP
from the dense-granules and platelet aggregation. P-
selectin release was assessed as described earlier [30]. The PRP
was incubated with 1 mM aspirin at 37uC for 30 minutes and then
platelets were isolated by centrifugation, washed twice and finally
resuspended in HEPES-buffered Tyrode’s solution without
calcium, pH 7.4 containing 0.2% bovine serum albumin and
apyrase (0.1 U/ml). Washed platelets (1–1.5610
6) were incubated
with 10 ml of FITC-conjugated anti-CD62P (P-selectin) antibody
solution for 30 minutes at 37uC without stirring. Expression of P-
selectin on platelet surface was quantified by flow cytometry
(FACSCalibur, Becton-Dickinson) and the Cellquest software
program [30,32]. Secretion of ATP from the dense granules was
assessed by a luminescence method using a luciferin/luciferase kit
from Chrono-Log Corporation (Havertown, PA) [30]. The
luciferin/luciferase reagent was added to platelets one minute
prior to addition of thrombin. Platelet aggregation was monitored
as reported earlier [30,33] using a Lumi-Aggregometer at 37uC
and a stirring speed of 900 rpm.
Measurement of platelet cyclic AMP levels. Washed
human platelets were incubated with a-PGG prior to stimulation
with thrombin or ADP and platelet cyclic AMP levels were
quantified using the procedure detailed earlier [30,34]. The
reaction was terminated by adding an equal volume of ice-cold
12% trichloroacetic acid [30,35]. The samples were centrifuged in
an Eppendorf micro-centrifuge for 5 minutes. The supernatants
were collected and washed three times with 5 ml of water-
saturated diethyl ether. The platelet cyclic AMP levels were
quantified using cyclic AMP enzyme-immunoassay kits from
enzyme-immunoassay kits from Cayman Chemical, Ann Arbor,
MI, USA.
Assessment of phosphorylation of insulin receptors, IRS-
1and Akt. Immuno-precipitation and Western blotting of
insulin receptors and IRS-1 was performed as described by
Ferreira et al. [15]. The effect of a-PGG on agonist-induced
phosphorylation of Akt was assessed in samples pre-treated with a-
PGG and then stimulated with thrombin. The reactions were
terminated by adding 56 sample buffer and proteins were
separated by SDS-PAGE. Western blots were probed with anti-
Akt and anti-p-Akt antibodies.
Measurement of Platelet cytosolic calcium. Platelet
cytosolic calcium levels were quantified by using Fura 2/AM-
loaded platelets. Washed human platelets were incubated with
3 mM Fura 2/AM at room temperature for 30 min. After incuba-
tion, platelets were washed twice and resuspended in a modified
Tyrode’s solution, pH 7.4. Fluorescence was recorded with a
Hitachi F-2000 fluorescence spectrophotometer and calcium levels
were quantified as described earlier [33,36].
Statistical analysis. Data are expressed as means 6 SD or
SEM as described in figure legend. A p value of ,0.05 indicates
statistically significant difference between the control and a-PGG
treated samples.
Results
Insulin or a-PGG induced phosphorylation of insulin
receptors and IRS-1
Binding of insulin to its receptors on platelet induces auto-
phosphorylation of the b-subunits of insulin receptor and
conformational changes that enhance the insulin receptor tyrosine
kinase activity leading to phosphorylation of target proteins
notably the IRS-1 [15]. We have shown earlier that a-PGG binds
to insulin receptors and induces phosphorylation of IR-b in CHO-
IR cells [28]. We investigated the possibility that a-PGG may
induce phosphorylation of insulin receptors and IRS-1in human
platelets. A five minute incubation of washed human platelets with
insulin (100 nM) or a-PGG (10 mM) induced 2.6 and 4.8 fold
increase in phosphorylation of insulin receptor and 2.4 and 3.3
fold increase in phosphorylation of IRS-1 (Fig. 1). The ability of a-
PGG to induce phosphorylation of insulin receptors and IRS-1
suggest that a-PGG mimics the action of insulin on platelets.
Insulin and a-PGG inhibited in vitro platelet aggregation
induced by ADP or collagen
It has been shown that insulin induces phosphorylation of its
receptors on platelets and inhibits platelet activation [11,15,37].
Based on our data that a-PGG induces phosphorylation of insulin
receptors (Fig. 1) we investigated the possibility that a-PGG may
mimic the antiplatelet actions of insulin. A five-minute pre-
incubation of platelets with insulin (Fig. 2A, B) or a-PGG (Fig. 2D,
E) inhibited ADP or collagen induced aggregation. Recently IGF-
1 has been shown to enhance platelet aggregation induced by ADP
and other agonists [38,39]. We investigated the effects of IGF-1
and insulin on platelet aggregation in the same platelet
preparations and observed that while insulin inhibited ADP
(Fig. 2A) or collagen (Fig. 2B) induced platelet aggregation, IGF-1
enhanced platelet aggregation (Fig. 2C). Moreover, the IGF-1
Antiplatelet Action of an Insulin Mimetic Molecule
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reversed by PPP, an IGF-1R antagonist (Fig. 2C). These findings
show that insulin inhibits whereas IGF-1 enhances agonist induced
platelet activation. Incubation of platelets with a-PGG alone did
not induce platelet aggregation (Fig. 2F).
Evidence that a-PGG inhibited secretion from platelet
a- and the dense-granules
Secretion from the dense- and a-granules plays critical roles in
platelet aggregation. We tested the possibility that a-PGG inhibits
platelet aggregation by inhibiting granular secretion. Pre-incuba-
tion of human platelets with a-PGG blocked thrombin-induced
release of P-selectin from a-granules and secretion of ATP
from dense granules as well as aggregation in a concentration-
dependent manner (Fig. 3). The ability of a-PGG to inhibit
secretion suggests that a-PGG inhibits platelet aggregation, at least
in part, by inhibiting secretion.
a-PGG inhibited agonist induced lowering of cyclic AMP
and rise in cytosolic calcium
Agonists such as thrombin or ADP, secreted upon activation of
platelets by a variety of agonists, stimulate Gia2 [40]. A G protein
that inhibits adenylyl cyclase and thereby lowers basal cAMP
levels in platelets [15]. Insulin has been shown to inhibit thrombin-
induced lowering of cyclic AMP [15]. We investigated the
possibility that a-PGG inhibits platelet activation by blocking
agonist induced decrease in basal cAMP levels. Incubation of
platelets with a-PGG (10 mM) alone did not alter cAMP (pmol/
10
8 platelets) levels (4.6460.13) as compared to control samples
(4.5460.33). Addition of thrombin (0.1 U ml
21) or ADP (10 mM)
to platelets decreased cAMP levels by 24% (p,0.03) and 22%
(p,0.02) respectively. A higher concentration of thrombin
(0.25 U ml
21) has been shown to induce a greater decrease
(40%) in cyclic AMP levels [15]. Pre-incubation of platelets with a-
PGG completely blocked thrombin- or ADP-induced lowering of
cAMP levels (Table 1). Addition of PGE1 to washed human
platelets increased cAMP level to 24.3362.86 pmol/10
8 platelets.
Incubation of platelets with a-PGG prior to addition of PGE1 did
not affect the increase in cAMP (Table 1). These findings suggest
that a-PGG affects Gi mediated inhibition but not the Gs
mediated activation of adenylyl cyclase.
Insulin has been shown to inhibit ADP as well as thrombin
induced rise in cytosolic calcium in platelets [15]. We investigated
the effect of a-PGG on thrombin-induced calcium mobilization
using Fura 2/AM loaded washed human platelets. Addition of a-
PGG (10 mM) alone to platelets did not alter the basal calcium
levels (33.764.2 nM). Stimulation of platelets with thrombin
(0.1 U ml
21) increased the cytosolic calcium level by 362%. Pre-
incubation of platelets with a-PGG decreased thrombin induced
rise in cytosolic calcium in a concentration-dependent manner
(Fig. 4). These data suggest that a-PGG inhibits platelet activation
by preventing agonist-induced lowering of cyclic AMP and the rise
the cytosolic calcium.
a-PGG inhibited agonist-induced phosphorylation of Akt
Insulin has been reported to induce phosphorylation of Akt
[41]. We therefore investigated the possibility that a-PGG may
also induce phosphorylation of Akt. Incubation of washed human
platelets with insulin or a-PGG alone for 6 minutes induced
phosphorylation of Akt (Fig. 5) without inducing platelet
aggregation (Fig. 2F). However, collagen, an inducer of aggrega-
tion, induced significantly greater phosphorylation of Akt than
insulin or a-PGG (Fig. 5). Agonist induced stimulation of Gi not
only lowers cAMP via Gia2 but also activates PI3-K via its bc-
subunit, leading to phosphorylation of Akt [35]. We investigated
the possibility that a-PGG by blocking activation of Gi also
prevents phosphorylation of Akt. Pre-incubation of platelets with
a-PGG inhibited phosphorylation of Akt induced by collagen
(Fig. 5) or thrombin (data not shown). These findings suggest that
a-PGG inhibits platelet activation, at least in part, by inhibiting
phosphorylation of Akt.
Administration of a-PGG inhibited ex vivo platelet
aggregation induced by ADP or collagen
We have shown earlier that oral administration of a-PGG
induces hypoglycemia in db/db mice [28,29]. We investigated the
possibility that oral administration of a-PGG may also inhibit ex
vivo platelet aggregation. Blood from wild type mice was drawn at
30 minutes after oral administration of a-PGG (20 mg kg
21)o r
saline and platelet aggregation was monitored in platelet-rich
plasma. The data in Fig. 6 show that platelet aggregation induced
by ADP or collagen is blocked in platelets from mice treated with
a-PGG.
Discussion
This study was undertaken to investigate the effects and the
mechanisms of the anti-platelet actions of 1,2,3,4,6-penta-O-
galloyl-a-D-glucopyranose (a-PGG), an orally effective hypogly-
cemic small molecule that has been shown to bind to insulin
receptors and activate the insulin-induced signaling i.e. phosphor-
ylation of b-subunits of insulin receptor and IRS-1 in CHO-IR
cells [28] and RKO cells [42]. The data in this report show that
insulin as well as a-PGG induced phosphorylation of insulin
receptors and IRS-1 in human platelets (Fig. 1). These findings
confirm an earlier report that insulin mediated signaling in
platelets involves phosphorylation of insulin receptors and IRS-
1[15] and demonstrate for the first time that a-PGG mimics the
action of insulin on platelets. The ability of a-PGG to mimic the
action of insulin taken together with our earlier findings that a-
Figure 1. Insulin or a-PGG induced phosphorylation of insulin
receptors and IRS-1. Washed human platelets were incubated with
insulin (100 nM) or a-PGG (10 mM) for five and ten minutes. The
reactions were stopped by adding lysis buffer and the total and
phosphorylated insulin receptors (A) and total IRS-1 and phosphorylat-
ed IRS-1 (B) were visualized after immuno-precipitation and Western
blotting. The phosphorylation of insulin receptors and IRS-1 was
quantified by densitometry.
doi:10.1371/journal.pone.0026238.g001
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PLoS ONE | www.plosone.org 3 November 2011 | Volume 6 | Issue 11 | e26238Figure 2. Insulin or a-PGG inhibited in vitro platelet aggregation induced by ADP or collagen. Insulin (A, B) or IGF-1 (C) was added to PRP
and a-PGG (D, E) was added to washed human platelets five min prior to stimulation with ADP or collagen and aggregation was monitored using an
aggregometer from Chrono-Log-Corporation (Havertown, PA, USA). The aggregation tracings are representative of three experiments.
doi:10.1371/journal.pone.0026238.g002
Figure 3. a-PGG inhibited thrombin induced secretion from the a- and dense-granules and platelet aggregation. Washed human
platelets were stimulated with thrombin (0.1 U mL
21) in the presence or absence of a-PGG and expression of P-selectin (A) and secretion of ATP (B)
and platelet aggregation (C) was monitored as detailed in Experimental Procedures. The results are reported as means 6 SD for P-selectin expression
(n=3). ATP secretion and aggregation tracings are representative of three experiments.
doi:10.1371/journal.pone.0026238.g003
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and (b) displaced insulin from insulin receptors in a concentration-
dependent manner with an IC50 of 1061 mM [28] suggest that a-
PGG binds to insulin receptors to induce insulin like anti-platelet
actions. The possibility that a-PGG binds to insulin receptors is
further supported by our findings that both insulin and a-PGG not
only induce glucose transport in adipocytes [28] but a-PGG
competes with insulin for glucose transport [28]. The ability of
HNMPA-(AM)3, an inhibitor of the insulin receptor (IR) tyrosine
kinase, to block a-PGG-induced glucose transport also implies that
a-PGG mediated actions involve binding to insulin receptors [28].
In addition our recent findings that a-PGG induces apoptosis in
human colon cancer RKO cells and that the a-PGG induced
apoptosis is reduced when RKO cells are treated with siRNA
specific to insulin receptor but not the non-specific control siRNA
[42] provide conclusive evidence that a-PGG acts by binding to
insulin receptors.
Our findings that both insulin and a-PGG inhibited ADP or
collagen induced platelet aggregation (Fig. 2) not only are in
agreement with reported antiplatelet actions of insulin but also
show for the first time that an insulin mimetic small molecule is
also capable of inhibiting platelet aggregation. However, a-PGG
does not appear to mimic the actions of insulin-like growth factor
(IGF-1). Our findings that IGF-1 enhanced ADP-induced platelet
aggregation (Fig. 2C) are in agreement with earlier reports that
IGF-1 enhances platelets aggregation induced by ADP and other
agonists [38,39]. Moreover, our observation that the IGF-1
mediated increase in ADP-induced platelet aggregation is reversed
by PPP, an IGF-1R antagonist, (Fig. 2C) confirms the specificity of
the IGF-1 action on platelet activation. These findings suggest that
insulin and IGF-1 exert opposite effects on platelet activation by
ADP. It takes only 0.2 nM IGF-1, as compared to 160 nM insulin,
to displace 50% of the IGF-1 from its receptors [43]. The 800-fold
difference between the concentration of IGF-1 and insulin needed
to displace IGF-1 from its receptors suggests that insulin and IGF-
1 induce signal transduction via their specific receptors. The
mechanisms underlying the opposite responses in platelets induced
by insulin and IFG-1 remain to be investigated.
Inhibition of secretion from platelet granules diminishes the
aggregation response and insulin has been shown to inhibit
thrombin-induced release of P-selectin from platelet granules [41].
Our observations that a-PGG inhibited thrombin induced release
of P-selection from the a-granules, secretion of ATP from the
dense granules as well as aggregation in a concentration-
dependent manner (Fig. 3) suggest that a-PGG, at least in part,
inhibits platelet aggregation by preventing the release of platelet
granular contents.
Agonist-induced platelet activation (secretion, aggregation)
involves multiple biochemical pathways leading to a rise in
cytosolic calcium and cyclic AMP plays a critical role in regulation
of cytosolic calcium levels. Increase in cyclic AMP level inhibits the
agonist-induced rise in platelet cytosolic calcium whereas lowering
Table 1. a-PGG inhibited ADP- or thrombin-induced lowering of cyclic AMP.
Additions PBS + PBS PBS + ADP
PBS a-
PGG a-PGG + ADP PBS + Thrombin a-PGG + Thrombin PBS + PGE1 a-PGG + PGE1
Mean 4.54 3.44* 4.64 4.28 3.54* 4.58 24.33 25.08
SD 0.33 0.66 0.13 0.30 0.45 0.47 2.86 1.61
ADP (10 mM), thrombin (0.1 U ml
21) or PGE1 (1 mM) induced changes in platelet cyclic AMP (pmoles/10
8 platelets) levels were quantified in the presence or absence of
a-PGG (10 mM) using enzyme-linked assay kits as described in Experimental Procedures. ADP and thrombin decreased basal cyclic AMP levels by 24% (*p,0.03) and
22% (*p,0.02) respectively. a-PGG blocked ADP and thrombin induced decrease in cyclic AMP levels.
doi:10.1371/journal.pone.0026238.t001
Figure 4. a-PGG inhibited thrombin induced rise in cytosolic
calcium. Changes in cytosolic calcium were quantified in Fura2/AM
loaded platelets. Platelets were incubated with a-PGG (3 or 10 mM) prior
to stimulation with thrombin (0.1 U mL
21) and changes in calcium
levels were recorded by fluorescence spectrometry as described in
Experimental Procedures. The results are reported as means 6 SE
(n=4).
doi:10.1371/journal.pone.0026238.g004
Figure 5. a-PGG inhibited collagen-induced phosphorylation of
Akt. Washed human platelets were stimulated with collagen
(1.0 mgm L
21) in the presence or absence of a-PGG (10 mM). Lysis
buffer was added to samples at 6 min to terminate reactions. Total Akt
and p-Akt were visualized after PAGE and Western blotting as described
in the Experimental Procedures. The b-actin was used as a loading
control.
doi:10.1371/journal.pone.0026238.g005
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reported not only to inhibit thrombin-induced lowering of cyclic
AMP but also to prevent thrombin-induced rise in platelet
cytosolic calcium [15]. Our findings that a-PGG not only induced
phosphorylation of IRS-1 but also inhibited thrombin- or ADP-
induced lowering of cyclic AMP in platelets (Table 1) and the rise
in cytosolic calcium (Fig. 4) further support the possibility that a-
PGG mimics the antiplatelet actions of insulin.
Phosphorylation of Akt plays a critical role in the secondary or
irreversible platelet aggregation [35,44,45,46]. Insulin and throm-
bin both induce phosphorylation of Akt in platelets [41]. However,
insulin mediated phosphorylation of Akt does not induce platelet
aggregation [41]. Our findings that incubation of platelets with a-
PGG alone induced phosphorylation of Akt (Fig. 5) but did not
induce platelet aggregation (Fig. 2F) suggest that a-PGG induced
phosphorylation of Akt in the absence of pro-aggregation signals
such as agonist induced lowering of cyclic AMP and or
mobilization of calcium is not sufficient to induce platelet
activation. The importance of the detectable phosphorylation of
Akt, in the absence of any platelet activation (Fig. 2F), induced by
a-PGG alone remains to be determined.
In spite of its ability to induce phosphorylation of Akt in the
absence of any agonist, a-PGG inhibited collagen-induced
phosphorylation of Akt (Fig. 5) as well as platelet aggregation
(Fig. 2E). Platelet aggregation agonist such as ADP and thrombin
induces activation of Gi leading to its dissociation into Gia2 and
the bc sub-units. The Gia2 lowers cyclic AMP whereas the bc sub-
units induce phosphorylation of Akt [35]. Our findings that a-
PGG inhibits both the lowering of cyclic AMP (Table 1) and
phosphorylation of Akt (Fig. 5) suggest that a-PGG inhibits platelet
activation by blocking agonist induced activation of Gia2.
The in vitro anti-platelet activity of a-PGG (Figs. 2,3) taken
together with its ability to induce hypoglycemia when given orally
[28] suggests that oral administration of a-PGG may be effec-
tive in inhibiting platelet aggregation. Our findings that orally
administered a-PGG inhibited ex vivo platelet aggregation induced
by ADP or collagen (Fig. 6) demonstrate that a-PGG is an orally
effective anti-platelet agent. The dual hypoglycemic and anti-
platelet properties of a-PGG suggest that insulin mimetic small
molecules may be developed as orally effective anti-platelet agents
for management of thrombotic complications in diabetic patients.
In summary these findings suggest that a-PGG inhibits platelet
activation, at least in part, by mimicking the action of insulin i.e.
by inducing phosphorylation of insulin receptor and IRS-1 leading
to inhibition of agonist-induced lowering of cAMP, rise in cytosolic
calcium and the phosphorylation of Akt.
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